Recent items - Journal of Investigative Dermatology
Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor.
03/09/2010 17:33
Related Articles Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor. J Invest Dermatol. 2010 Sep 2; Authors: Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M, Iiyama T, Asao N, Digiovanni J, Sano S Epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3, and increased levels of cytokines and growth factors that promote Stat3 activation have been found [...]
03/09/2010 17:33
Related Articles Stat3 as a Therapeutic Target for the Treatment of Psoriasis: A Clinical Feasibility Study with STA-21, a Stat3 Inhibitor. J Invest Dermatol. 2010 Sep 2; Authors: Miyoshi K, Takaishi M, Nakajima K, Ikeda M, Kanda T, Tarutani M, Iiyama T, Asao N, Digiovanni J, Sano S Epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3, and increased levels of cytokines and growth factors that promote Stat3 activation have been found [...]
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model.
27/08/2010 13:33
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model. J Invest Dermatol. 2010 Aug 26; Authors: Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A The Kv1.3 channel is important in the activation and function of effector memory T cells. Recently, specific blockers of the Kv1.3 channel have been developed as a potential therapeutic option for diverse autoimmune diseases. In psoriatic lesions, most lymphocytes are memory effector T cells. [...]
27/08/2010 13:33
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model. J Invest Dermatol. 2010 Aug 26; Authors: Gilhar A, Bergman R, Assay B, Ullmann Y, Etzioni A The Kv1.3 channel is important in the activation and function of effector memory T cells. Recently, specific blockers of the Kv1.3 channel have been developed as a potential therapeutic option for diverse autoimmune diseases. In psoriatic lesions, most lymphocytes are memory effector T cells. [...]
Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis.
30/07/2010 12:39
Related Articles Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis. J Invest Dermatol. 2010 Jul 29; Authors: Li Y, Liao W, Cargill M, Chang M, Matsunami N, Feng BJ, Poon A, Callis-Duffin KP, Catanese JJ, Bowcock AM, Leppert MF, Kwok PY, Krueger GG, Begovich AB Testing of approximately 25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a genetic association study has identified three psoriasis gene [...]
30/07/2010 12:39
Related Articles Carriers of Rare Missense Variants in IFIH1 Are Protected from Psoriasis. J Invest Dermatol. 2010 Jul 29; Authors: Li Y, Liao W, Cargill M, Chang M, Matsunami N, Feng BJ, Poon A, Callis-Duffin KP, Catanese JJ, Bowcock AM, Leppert MF, Kwok PY, Krueger GG, Begovich AB Testing of approximately 25,000 putative functional single-nucleotide polymorphisms (SNPs) across the human genome in a genetic association study has identified three psoriasis gene [...]